Objective: The cytokine cardiotrophin-1 (CT-1) has previously been shown to protect cultured cardiocytes from cell death induced by serum removal or hypoxia when administered prior to the damaging stimulus. We wished to test whether a similar protective effect could be observed if CT-1 was added after the ischaemic period and to investigate the signalling pathways involved in the protective effect when CT-1 is given prior to or after ischaemia. Methods: We therefore examined the protective effect of CT-1 in cultured rat cardiocytes exposed to simulated ischaemia followed by reoxygenation when CT-1 was administered either prior to simulated ischaemia or at reoxygenation. Results: We show that CT-1 can exert a protective effect against the damaging effects of simulated ischaemia / reoxygenation both when added after the simulated ischaemia at reoxygenation (P,0.05 in trypan blue, TUNEL and annexin V assays) or when added prior to the simulated ischaemia (P,0.05). In both cases, these protective effects are blocked by an inhibitor of the p42 / p44 MAPK pathway (P,0.05 in all assays). Conclusion: CT-1 can protect cardiac cells when added either prior to simulated ischaemia or at the time of reoxygenation following simulated ischaemia and these effects are dependent upon its ability to activate the p42 / p44 MAPK pathway. Hence CT-1 may have therapeutic potential when added at the time of reperfusion following ischaemic damage.
Introduction
though the IL-6, CNTF and OSM receptors contain in addition a specific subunit which is unique to each of these Cardiotrophin-1 (CT-1) was initially isolated as a factor, receptors [5, 6] , LIF and CT-1 and in certain cells, OSM which was capable of inducing cardiac myocyte hypershare a common second receptor component, which is trophy in vitro [1] , and was subsequently shown to have a known as LIF receptor sub-unit b [3, 7] . Following binding similar effect when injected into adult mice [2] .
to the receptor, members of the IL-6 family activate both Subsequent studies established that CT-1 is a member of the MAP kinase pathway and the Jak / STAT pathway a family of cytokines including interleukin-6 (IL-6), resulting respectively in the phosphorylation of the tranleukaemia inhibitory factor (LIF) ciliary neurotrophic scription factors NF-IL6 and STAT-3 allowing them to factor, (CNTF) oncostatin M (OSM) and IL-11 [3, 4] . The stimulate transcription [5, [8] [9] [10] . receptor for each of these factors contains a common As well as its potentially damaging hypertrophic effects, component known as gp130 (for review see [5, 6] ). Al-CT-1 also has significant protective effects. The apoptotic death of unstressed cardiac myocytes in defined serum-free medium can be reduced by treatment with CT-1 [11, 12] and this effect was inhibited by inactivation of p42 / p44 378C producing a PO level of 4 mmHg, 0.2% final 2 MAP kinase, which had no effect on the hypertrophic oxygen concentration. This buffer is a modification of that response to CT-1 [12] . This effect, together with the devised by Esumi et al. [16] to simulate the extra cellular expression of CT-1 in the early mouse embryonic heart milieu that occurs during myocardial ischaemia in vivo tube, suggests that CT-1 may have significant effects on resulting in the appropriate concentrations of potassium, cardiac survival which are important during heart develophydrogen and lactate ions. ment [11] . Moreover, CT-1 may also play a key role in CT-1 at a concentration of 2 ng / ml was added to the protecting cardiac cells against stressful stimuli. Thus, cardiac myocytes 0, 30, 60 and 120 min prior to a lethal treatment of cultured neonatal cardiocytes with CT-1 simulated ischaemic insult and then removed just prior to protects them against subsequent exposure to thermal or the insult. For assays of the protective effect of CT-1 hypoxic stress both in terms of the total amount of cell added prior to ischaemia, the cells were analysed immedideath observed and the extent of apoptosis [13] .
ately after the ischaemic period. Subsequent to this injury Hence, we demonstrate for the first time that CT-1 can cell survival was assessed by trypan blue exclusion and have a protective effect when added at the time of apoptotic nuclei were assayed by the end labelling of DNA reoxygenation following simulated ischaemia as well as 39 ends with dUTP-FITC using a modification of the when added prior to the ischaemic period and that the TUNEL method [17] . protective effects observed when CT-1 is added either
To investigate the downstream signalling pathways, prior to or after the simulated ischaemia are blocked by an which mediate CT-1 cardioprotection against ischaemic inhibitor of the p42 / p44 MAPK pathway.
injury, the cardiac myocytes were incubated for 10 min in 1 ml of minimal medium containing signal transduction inhibitors, prior to a 30-min incubation with 2 ng / ml of 2. Materials and methods CT-1. The MEK1 inhibitor (PD98059) (New England Biolabs Inc, Beverly MA 01915) has been shown to act in 2.1. Cell culture vivo as a highly selective inhibitor of MEK 1 activation and the p44 / p42 MAP kinase cascade [18] . The inhibitor Cardiomyocytes from the hearts of 2-day-old neonatal was stored at 2208C at a concentration of 100 mM and rats (Sprague-Dawley), were prepared by a modification was used at a concentration of 50 mM. A highly specific of a previously published protocol [14] . This investigation inhibitor of p38 MAP kinase (SB 203580 (Calbiochem)) conforms with UK Home Office Guidelines and UCL was stored in the dark at a concentration of 100 mM in 50 Animal Ethical Committee procedures for animal work. mg / ml DMSO and was used at a concentration of 10 mM The cells were dispersed in a series of incubations at 378C [19] . Following the lethal ischaemic insult the cardiac in a nominally calcium free, HEPES-buffered salt solution myocytes were assessed for cell survival by trypan blue containing pancreatin (0.6 mg / ml, Gibco-BRL) and type II exclusion and apoptotic nuclei were assessed by the end collagenase (0.5 mg / ml at approximately 266 units / mg, labelling of DNA 39 ends with dUTP-FITC using a Worthington Biochemical Corporation). The dispersed modification of the TUNEL method [17] . cells were preplated for 1 h to allow contaminating fibroblasts to attach. The myocytes free within the culture media were plated on 24 well gelatin-coated plates at a 2.3. Reoxygenation 5 density of 1310 cells / well. The cardiac myocytes were cultured at 378C, 21% O 25% CO in 4:1 Dulbecco's For analysis of the protective effect of CT-1 added at the 2 2 Modified Eagles medium / medium 199 (Gibco-BRL) suptime of reoxygenation, cardiac cell cultures were exposed plemented with 10% (v / v) horse serum, 5% (v / v) fetal calf to 6 h of lethal ischaemia as described above and then serum and 1% (v / v) penicillin / streptomycin for 24 h. The incubated in a normoxic environment for 2 h (reoxygenamedia was then replaced with low serum (1% v / v FCS) tion). At the point of reoxygenation the ischaemic buffer Dulbecco's modified medium / medium 199 with penicillin / was removed and replaced with 1 ml minimal media with streptomycin (minimal media) for 48 h. At this point the and without the addition of 2 ng / ml of CT-1 for 2 h. To cells were ready for experimentation, as a spontaneous investigate the downstream signalling pathway which culture of beating myocytes had formed.
mediates CT-1 cardioprotection in reperfusion injury the cardiac myocytes were incubated for 10 min in 1 ml of 2.2. Simulated ischaemia minimal medium containing signal transduction inhibitors, prior to the 2-h incubation with 2 ng / ml of CT-1. To simulate ischaemia in vitro, cultured cardiocytyes Following reoxygenation, the cardiac myocytes were aswere incubated in 1 ml of simulated ischaemia buffer (137 sessed for cell survival by trypan blue exclusion and mM NaCl, 12 mM KCl, 0.49 mM MgCl , 0.9 mM CaCl .2 apoptotic nuclei were assessed by the end labelling of 2 2 H O, 4 mM HEPES, 20 mM sodium lactate, pH6.2: [15] ) DNA 39 ends with dUTP-FITC using a modification of the 2 for 6 h in an atmosphere of 5% CO and 95% argon at TUNEL method. C nitrocellulose membranes and then probed for 2 h at Apoptotic nuclei were assessed by the end labelling of room temperature using antibodies specific for phos-DNA 39 ends with dUTP-FITC, using a modification of the phorylated / active ERK1 / 2, p42 / 44 and STAT3. The TUNEL method [17] . For TUNEL, cardiac myocytes were membranes were washed in PBS / 0.05% (v / v) Tween and plated onto 1% gelatin (Sigma)-coated 24-well tissue incubated with a peroxidase-conjugated antibody. Imculture dishes and TUNEL assays were performed after the munoreactive bands were visualised by enhanced chemicells were fixed in 4% paraformaldehyde for 30 min at luminescence (ECL). The relative protein levels were 258C and washed with PBS three times. Terminal deoxydetermined using densitometry (Bio Rad) normalising to nucleotidyl transferase reaction solution, containing 2 mM the actin band on a duplicate Coomassie Brilliant Blue fluorescein-conjugated dUTP and 10 units of terminal R250 (BDH) stained gel and probing the membranes with deoxynucleotidyl transferase (Boehringer Mannheim) was anti-actin antibody. added to the cells for 2 h in a 378C humidified incubator. After washing with PBS the cells were then imaged with 2.7. Antibodies for western blotting fluorescent microscopy.
Anti-active MAPK pAb, rabbit ERK1 / 2, p42 / 44 anti-2.5. significance was assumed when the P-value was less than of 250 cells were scored, three times per well of cells. 0.05. Differences among means were compared within the treatment groups using Bonferroni's post-hoc test. The failed to exclude trypan blue in control cultures exposed to experiments were repeated as indicated in the figure simulated ischaemia and CT-1 pre-treatment for different legends, each n number corresponds to the mean of three periods reduced this to 51.2% (30 min), 42.8% (60 min) or random fields per well of cells with a minimum of 250 38.0% (120 min). In contrast, no effect was observed when cells scored per view. In all cases, comparisons were the CT-1 was added immediately before the stressful performed between untreated samples and those treated stimulus and then removed. with CT-1 or between a sample treated with an inhibitor
In these and all other experiments, the total number of and the same treatment without the inhibitor.
trypan blue positive and negative cells counted at the end of the experiment after ischaemia was the same as the number of cells counted prior to treatment indicating that 3. Results dead cells were not being missed by this procedure (data not shown). Although these experiments involved analysIn our previous experiments [13] we observed a protecing the cells immediately after the period of simulated tive effect of CT-1 when it was added 24 h before ischaemia, the protective effect of a 30 min pre-treatment exposure of cultured cardiocytes to simulated ischaemia.
with CT-1 was also observed when cells were exposed to To investigate the time required for this protective effect, simulated ischaemia followed by reoxygenation for 24 h we added CT-1 at progressively shorter intervals before prior to harvesting confirming that this effect could be exposure to the simulated ischaemia. As shown in Fig. 1 , a observed after a long period of reoxygenation (Fig. 2) . As clear protective effect against the cell death induced by this expected, enhanced cell death was observed in the control stress was observed even when the CT-1 was added only cells following exposure to reoxygenation (P,0.05, com-30 min before the stressful stimulus and then removed pare Figs. 1 and 2) since such enhanced cell death during prior to exposure to the stress. Thus 64.8% of the cells reperfusion following ischaemia has previously been observed in the heart in vivo [20] . Although we previously observed that the protective effect of CT-1 was correlated with its ability to induce enhanced synthesis of the heat shock proteins hsp70 and hsp90 [13] the rapid protective effect of CT-1 suggested that this might be independent of protein synthesis. To Fig. 1 . CT-1 (2 ng / ml) was added to the cardiac myocytes and either immediately removed prior to a 6 h simulated lethal ischaemic stress or the cells were incubated with CT-1 under normoxic conditions for 30, 60 or 120 min prior to the stress. The cells were then harvested and cell death was assessed by trypan blue exclusion as described in Materials and Fig. 2 . Cardiac myocytes were cultured with or without CT-1 for 30 min methods. The immediate addition and then removal of CT-1 failed to under normoxic conditions. The CT-1 was removed from the cells, which protect the cardiac myocytes from simulated lethal ischaemic stress were then exposed to a 6 h simulated lethal ischaemic stress. The cells (P50.53 n59) compared to the untreated cells exposed to the same were then incubated in growth media for 24 h under normal conditions. stress. An incubation period of 30 min with CT-1 resulted in protection Subsequently cell death was assessed by trypan blue exclusion. CT-1 from simulated lethal ischaemic stress (P50.005, n510) which was also protected the cardiac myocytes from cell death for 24 h of reoxygenation observed when the CT-1 was incubated with the cells for 60 (P50.0009, following ischaemic injury as cell death decreased from 82.8% in the n57) and 120 min (P50.00007 n58). P Value for ANOVA group untreated cells compared to 48.2% in the CT-1 treated cells (*P,0.05). investigate whether a protective effect of CT-1 could be contrast no phosphorylation of p38 MAPK or JNK was obtained in the absence of de novo protein synthesis, CT-1 observed in the CT-1 treated cells using a specific antibody was added to cardiac myocytes either alone or in the indicating that CT-1 does not significantly activate these presence of the protein synthesis inhibitor cycloheximide, pathways (data not shown). Hence both the p42 / p44 1 h prior to exposure to the stress. In all experiments on MAPK and Jak / STAT pathways are activated by CT-1 in the protective effect of CT-1 added prior to simulated our system. Enhanced phosphorylation of p42 / p44 MAPK ischaemia, cells were analysed immediately after the was also observed in cardiac cells exposed to ischaemia / period of simulated ischaemia. In these experiments (Fig. reoxygenation and treated with CT-1 compared to the level 3) the addition of cycloheximide had no effect on the observed in cells exposed to ischaemia / reoxygenation protective effect of CT-1 indicating that this effect does alone (panels c and d). not appear to depend upon de novo protein synthesis in the The protective effect of CT-1 against apoptosis in treated cells.
cardiocytes grown in serum-free medium has previously In view of the rapid protective effect of CT-1 and its been shown to be inhibited by PD98059, a specific lack of dependence upon protein synthesis, we wished to inhibitor of the p42 / p44 MAP kinase pathway which acts investigate the signalling pathways which were involved in by inhibiting the activity of the upstream activator of these the protective effect against simulated ischaemia and kinases MEK1. As expected, the enhanced phosphorylation which had not previously been investigated. Previous of p42 / p44 induced by CT-1 was blocked by addition of studies with members of the IL-6 family have indicated PD98059 ( Fig. 4c and d) .The protective effect of CT-1 that they can activate both the p42 / p44 MAP kinase against simulated ischaemia was therefore investigated pathway resulting in the phosphorylation of the transcripusing the trypan blue exclusion assay in the presence or tion factor NF-IL6 and the Jak / STAT pathway resulting in absence of this inhibitor as well as in the presence or the phosphorylation of the STAT-3 transcription factor absence of the p38 MAP kinase inhibitor SB203580 [19] . [5, [8] [9] [10] .
In these experiments (Fig. 5 ) the PD98059 p42 / p44 To confirm that these effects were also observed in our MAPK inhibitor completely blocked the protective effect system, we treated cardiocytes with CT-1 for various of CT-1 and a dose response experiment showed that this periods and assayed cell extracts by western blotting with inhibitory effect could be achieved at very low doses of the antibodies specific for the active phosphorylated form of inhibitor down to 0.5 mM (data not shown). In contrast, no the p42 / p44 MAPK enzymes or the phosphorylated form inhibition of the protective effect was observed with the of STAT-3. As illustrated in Fig. 4 the phosphorylated p38 MAPK inhibitor even though the concentration of this form of the p42 / p44 MAPK (ERK 1 / 2) enzymes was only inhibitor used was sufficient to block the p38 MAPK observed in the CT-1 treated cells (panel a) whilst enphosphorylation which occurs during reoxygenation (data hanced levels of phosphorylated STAT-3 were observed in not shown) in agreement with the work of others using this CT-1 treated cells compared to untreated cells (panel b). In inhibitor concentration [21, 22] . This suggests that, as with the protective effect against serum starvation, the protective effect of CT-1 against ischaemic stress involves the MEK1 kinase, which specifically activates the p42 / p44 MAP kinase pathway. No significant effect of PD98059 on cell survival was observed in the absence of CT-1 confirming that the effect of PD98059 specifically involved blocking the protective effect of CT-1. Abolition of p38 MAPK activity with SB 203580 did itself produce a protective effect (Fig. 5) in agreement with previous reports on the detrimental effects of activating this kinase [21, 23] . SB203580 had no effect on the protective effect of CT-1, suggesting that p38 MAPK was not involved in this effect, although the protective effect of SB203580 alone means that this cannot be definitively excluded.
As well as investigating the effect of the different Fig. 3 . CT-1 (2 ng / ml) was added to cardiac myocytes for 60 min in the inhibitors using the trypan blue exclusion assay, which presence and absence of cycloheximide (1 mg / ml). The CT-1 / cycloheximide was removed from the cells, which were then exposed to a 6 h measures total cell death, both necrotic and apoptotic, we simulated lethal ischaemic stress. The cells were then harvested and cell also utilised the TUNEL labelling assay to measure the death was assessed by trypan blue exclusion as described in the Materials effect on apoptotic cell death. In these experiments ( these experiments, CT-1 was added at the end of the period of simulated ischaemia and cells analysed after 2 h reoxygenation. Most interestingly, we found that CT-1 had a protective effect against both the total amount of cell death observed (Fig. 7) and the amount of apoptosis as measured by TUNEL labelling (Fig. 8) or staining with labelled annexin V (Fig. 9 ) when added at the time of reoxygenation. This is the first time that a protective effect of CT-1 has been demonstrated when it is added after rather than before the ischaemic stimulus. Moreover, this effect can be demonstrated both by assaying total cell death and by assaying apoptotic cell death using two assays which measure two different aspects of apoptosis, namely DNA degradation (TUNEL) and translocation of phosphatidyl serine to the plasma membrane (annexin V). As in the case of the protective effect observed when SB203580 (10 mM). The inhibitors were added to the cells 30 min before CT-1 was added before the period of simulated ischaemia, the addition of CT-1. The CT-1 and inhibitors were removed from the the protective effect observed during re-oxygenation was cells, which were then exposed to a 6 h simulated lethal ischaemic stress inhibited by PD98059, but not to the same extent by (I). The cells were harvested and cell death was assessed by trypan blue SB203580. This indicates that this effect is similarly likely exclusion as described in Materials and methods. CT-1 significantly protected the cardiac myocytes from ischaemic injury (P50.028) comto be dependent primarily upon activation of the p42 / p44 pared to untreated cells (NT). PD98059 inhibited the protective effect of MAP kinase pathway rather than upon the activation of the CT-1 (P50.0016). SB203580 had no effect on the protective effect of p38 MAP kinase pathway. It is possible however, that the CT-1 (P50.97). PD98059 alone had no significant effect on survival after p38 MAPK pathway may play some role since an effect of hypoxic / ischaemic stress whilst SB203580 alone was cardioprotective
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SB203580 on the protective effect of CT-1 was observed (P50.0007). P Value for ANOVA group differences 2310 . n56 for all treatments.
in the TUNEL assay. No statistically significant effect of Fig. 7 . Cardiac myocytes were exposed to simulated lethal ischaemic injury for 6 h. Immediately after this period, the stimulated ischaemic Fig. 8 . Cardiac myocytes were exposed to simulated lethal ischaemic buffer was removed and replaced with normal growth medium supinjury for 6 h. Immediately after this period, the simulated ischaemic plemented with CT-1 (2 ng / ml) in the presence and absence of PD98059 buffer was removed and replaced with normal growth medium sup-(50 mM), or SB203580 (10 mM). The inhibitors were added to the cells plemented with CT-1 (2 ng / ml) in the presence and absence of PD98059 10 min before the addition of CT-1. The cells were incubated under (50 mM), or SB203580 (10 mM). The inhibitors were added to the cells normoxic, oxygenated conditions for 2 h. Subsequent to this period the 10 min before the addition of CT-1. The cells were incubated under cells were harvested and cell death following ischaemia / reoxygenation normoxic, oxygenated conditions for 2 h. Subsequent to this period the (IR) was assessed by trypan blue exclusion as described in Materials and cells were harvested and apoptotic cell death was assessed by TUNEL methods, CT-1 significantly protected the cardiac myocytes from injury labelling as described in Materials and methods. CT-1 significantly when added at the point of reoxygenation (P50.016). PD98059 partially protected the cardiac myocytes from injury when added at the point of inhibited the protective effect of CT-1 (P50.0165) SB203580 had no reoxygenation (P50.0001). PD98059 inhibited the protective effect of effect on the protective effect of CT-1 (P50.938). PD98059 alone had no CT-1 (P50.001) and SB203580 (P50.0047) also had an inhibitory statistically significant effect on cell survival whilst SB203580 alone had effect. Neither of the inhibitors alone had any significant effect on the a protective effect (P50.015). P Value for ANOVA group differences number of TUNEL labelled cells observed in the absence of CT-1. P 27 25 3.44310 . n56 for each treatment.
Value for ANOVA group differences 1.57310 . n58 for each treatment.
PD98059 alone on cell survival was observed with any of As a result of intensive studies, it has been shown that the assays confirming that the effect of PD98059 was treatments such as pre-conditioning with a series of short specific for CT-1, as in the experiments involving preischaemic episodes or treatment with a variety of agents treatment with CT-1. A similar protective effect of CT-1 can be effective at minimising such damage in the intact added at reoxygenation was also observed in experiments animal. However, such treatments are effective at miniwhere the cells were incubated for up to 96 h in normal mising damage only if given prior to the severe ischaemic medium prior to assay confirming that it could be observed episode and are therefore limited in their clinical apfollowing prolonged periods of reoxygenation (data not plicability since the majority of individuals present with an shown). Interestingly, addition of CT-1 both prior to ongoing ischaemic episode. ischaemia and at the time of reoxygenation did not provide
Here we show for the first time that the cardiac cytokine enhanced protection compared to either treatment alone CT-1 can be effective at minimising the damage caused by (data not shown).
a period of simulated ischaemia followed by re-oxygenation when given at the time of re-oxygenation as well as prior to the ischaemic period. Hence, CT-1 is able to exert 4. Discussion a protective effect against the damage, which occurs during re-oxygenation following a period of simulated ischaemia. The development of methods for reducing the damage
To date no studies have demonstrated conclusively that suffered by individuals undergoing episodes of cardiac pharmacological agents given at the time of reperfusion ischaemia is evidently of central importance in cardiology.
can protect the myocardium from reperfusion induced demonstrated that CT-1 could minimise the apoptotic death of cardiocytes cultured in serum free medium [11, 12] and we have shown that CT-1 also reduces the extent of apoptotic cell death in cardiocytes exposed to stressful stimuli, whether it is added prior to the period of hypoxia [13] or at the time of re-oxygenation (this study). Cytokines of the IL-6 family such as CT-1 have previously been shown to activate both the p42 / p44 MAP kinase pathway and the Jak / STAT pathway [8] [9] [10] 33] and this was also observed in our study (Fig. 4) . In cardiocytes exposed to serum free medium, the protective effect of CT-1 against apoptosis is dependent upon its ability to activate p42 / p44 MAP kinase and appears to be independent of its activation of the Jak / STAT pathway [12] . In contrast, the hypertrophic effect of CT-1 was not inhibited by inhibition of the p42 / p44 MAPK pathway [11] . In the work presented here, we have similarly demonstrated that the protective effect of CT-1 against either simulated ischaemia or re-oxygenation can be abolished by treatment with PD98059, a specific inhibitor of the p42 / p44 MAP kinase pathway. Hence these novel protective effects are also likely to be dependent on this pathway. Further studies will be required in order to demonstrate lethal injury. Although controversial, some studies have the protective effect of CT-1 in the intact animal and in the demonstrated however that an inhibition of leukocyte ex vivo heart preparation. Similarly, it will be important to activation is useful at the time of reperfusion [24] . In identify the mechanisms by which CT-1 activation of the addition studies by Forman's group [25, 26] have suggested p42 / p44 MAP kinase pathway results in enhanced protecthat adenosine given at reperfusion in animal models can tion. This is of particular importance since it may well lead protect against lethal reperfusion injury although this was to a method of activating this protective pathway either not seen by others [27, 28] .
with CT-1 or related agents without activating the potenHowever recently we have investigated the ability of tially damaging hypertrophy pathway which is also actispecific factors to protect against injury when given at vated by CT-1, hence allowing therapeutic advantage to be reperfusion. In this respect we have recently demonstrated taken of the ability of CT-1 to have a protective effect that factors such as urocortin and insulin both appear able when given at the time of reperfusion following an to protect the myocardium directly if given at the onset of ischaemic episode. reperfusion in a similar manner to that observed using CT-1 in the present study [29, 30] .
It has been shown that reperfusion / re-oxygenation
